MedTrace Logo

Studying the Role of Brain Molecules for Decision Making

NCT04384562 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2024-05-08

No results posted yet for this study

Summary

The aim of the present project is to elucidate the neuropharmacological mechanisms underlying value (choice preference) and attention (choice randomness) processing in humans. More specifically, the investigators test whether dopaminergic, noradrenergic and cholinergic interventions affect neural and behavioral processing of valuation and attention during decision-making. The investigators do this by up-regulating dopaminergic, noradrenergic or cholinergic neurotransmission pharmacologically through administration of methylphenidate, reboxetine, or nicotine. We test the hypothesis that methylphenidate, reboxetine, or nicotine reduce choice randomness and that this effect is underpinned by an effect on attention and/or value processing.

Conditions

  • Decision Making
  • Healthy

Interventions

DRUG

Methylphenidate

A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.

DRUG

Reboxetine

A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.

DRUG

Nicotine gum

A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.

DRUG

Placebo pill

A placebo pill is administered only once.

DRUG

Placebo gum

A placebo gum is administered only once.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Philippe Tobler, PhD · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-17
Primary Completion
2021-12-13
Completion
2021-12-13

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04384562 on ClinicalTrials.gov